Top

Published in:

01-12-2014 | Original Contributions

Laparoscopic Adjustable Gastric Banding Reduces Subcutaneous Adipose Tissue and Blood Inflammation in Nondiabetic Morbidly Obese Individuals

Authors: Laura Iaffaldano, Carmela Nardelli, Vincenzo Pilone, Giuseppe Labruna, Andreina Alfieri, Donatella Montanaro, Maddalena Ferrigno, Maria Restituta Zeccolella, Nicola Carlomagno, Andrea Renda, Alfonso Baldi, Pietro Forestieri, Lucia Sacchetti, Pasqualina Buono

Published in: Obesity Surgery | Issue 12/2014

Abstract

Background

Significant and sustained excess weight loss (EWL) appears to reduce the risk of obesity-related comorbidities (insulin resistance, hyperlipidemia, and inflammation), but this has been primarily shown in adult diabetic obese patients. We evaluated whether the EWL obtained 3 years after laparoscopic adjustable gastric banding (LAGB) improves the metabolic phenotype in nondiabetic morbidly obese (NDMO) individuals from south Italy.

Methods

Serum and subcutaneous adipose tissue (SAT) samples from 20 obese individuals (median BMI = 41.5 kg/m²) before (T0) and after LAGB (T1) and from 10 controls (median BMI = 22.8 kg/m²) were taken. Serum leptin, adiponectin, C reactive protein (CRP), and main analyte levels were evaluated by routine methods or immunoassay. In SAT, adipocyte size was measured by hematoxylin/eosin staining, cluster of differentiation 68 (CD68) macrophage infiltration marker by immunohistochemistry, and adiponectin, adiponectin receptors 1 and 2, and interleukin 6 (IL6) messenger RNAs by qRT-PCR.

Results

The average EWL was 66.7 %, and CRP, triglycerides, hepatic markers, leptin levels, homeostasis model assessment, and the leptin/adiponectin ratio were lower (p < 0.05) at T1 than at T0. The expression of small adipocytes and adiponectin was increased (p < 0.05), and inflammation markers (CD68 and IL6) decreased (p < 0.05) at T1 vs. T0. At linear regression multivariate analysis, over 90 % (R ² = 0.905) of EWL (dependent variable) was explained by CD68, adiponectinemia, triglyceridemia, CRP, and total protein levels.

Conclusions

The EWL obtained 3 years after LAGB resulted in an improvement of lipid metabolism and a reduction of inflammation in NDMO patients, thereby decreasing the risk of obesity-associated diseases.

Available only for authorised users

Johnson AR, Milner JJ, Makowski L. The inflammation highway: metabolism accelerates inflammatory traffic in obesity. Immunol Rev. 2012;249(1):218–38. doi:10.1111/j.1600-065X.2012.01151.x.PubMedCentralPubMedCrossRef

Leal VO, Mafra D. Adipokines in obesity. Clin Chim Acta. 2013;419:87–94. doi:10.1016/j.cca.2013.02.003.CrossRef

Mc Tigue KM, Hess R, Ziouras J. Obesity in older adults: a systematic review of the evidence for diagnosis and treatment. Obesity (Silver Spring). 2006;14(9):1485–97.CrossRef

O’Brien PE, MacDonald L, Anderson M, et al. Long-term outcomes after bariatric surgery: fifteen-year follow-up of adjustable gastric banding and a systematic review of the bariatric surgical literature. Ann. Surg. Jan;257(1):87–94. doi:10.1097/SLA.0b013e31827b6c02.

Campos GM, Rabl C, Roll GR, et al. Better weight loss, resolution of diabetes, and quality of life for laparoscopic gastric bypass vs banding: results of a 2-cohort pair-matched study. Arch Surg. 2011;146(2):149–55. doi:10.1001/archsurg.2010.316.PubMedCrossRef

Favretti F, Segato G, Ashton D, et al. Laparoscopic adjustable gastric banding in 1,791 consecutive obese patients: 12-year results. Obes Surg. 2007;17(2):168–75.PubMedCrossRef

Pilone V, Mozzi E, Schettino AM, et al. Improvement in health-related quality of life in first year after laparoscopic adjustable gastric banding. Surg Obes Relat Dis. 2012;8(3):260–8. doi:10.1016/j.soard.2011.12.012.PubMedCrossRef

Dixon JB, Chuang LM, Chong K, et al. Predicting the glycemic response to gastric bypass surgery in patients with type 2 diabetes. Diabetes Care. 2013;36:20–6.PubMedCentralPubMedCrossRef

Cobourn C, Chapman MA, Ali A, et al. Five-year weight loss experience of outpatients receiving laparoscopic adjustable gastric band surgery. Obes Surg. 2013;36(1):20–6. doi:10.2337/dc12-0779.

10.

Bonora E, Kiechl S, Willeit J, et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck study. Diabetes. 1998;47(10):1643–9.PubMedCrossRef

11.

Labruna G, Pasanisi F, Nardelli C, et al. High leptin/adiponectin ratio and serum triglycerides are associated with an “at-risk” phenotype in young severely obese patients. Obesity (Silver Spring). 2011;19(7):1492–6. doi:10.1038/oby.2010.309.CrossRef

12.

Labruna G, Pasanisi F, Nardelli C, et al. UCP1–3826 AG + GG genotypes, adiponectin, and leptin/adiponectin ratio in severe obesity. J Endocrinol Investig. 2009;32(6):525–9. doi:10.3275/6108.CrossRef

13.

Norata GD, Raselli S, Grigore L, et al. Leptin: adiponectin ratio is an independent predictor of intima media thickness of the common carotid artery. Stroke. 2007;38(10):2844–6.PubMedCrossRef

14.

Faraj M, Havel PJ, Phelis S, et al. Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab. 2003;88(4):1594–602.PubMedCrossRef

15.

Trakhtenbroit MA, Leichman JG, Algahim MF, et al. Body weight, insulin resistance, and serum adipokine levels 2 years after 2 types of bariatric surgery. Am J Med. May;122(5):435–42. doi:10.1016/j.amjmed.2008.10.035.

16.

Knerr I, Herzog D, Rauh M, et al. Leptin and ghrelin expression in adipose tissues and serum levels in gastric banding patients. Eur J Clin Investig. 2006;36(6):389–94.CrossRef

17.

Moschen AR, Molnar C, Geiger S, et al. Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor alpha expression. Gut. 2010;59(9):1259–64. doi:10.1136/gut.2010.214577.PubMedCrossRef

18.

Bjursell M, Ahnmark A, Bohlooly YM, et al. Opposing effects of adiponectin receptors 1 and 2 on energy metabolism. Diabetes. 2007;56(3):583–93.PubMedCrossRef

19.

Yamauchi T, Nio Y, Maki T, et al. Targeted disruption of ADIPO-R1 and ADIPO-R2 causes abrogation of adiponectin binding and metabolic actions. Nat Med. 2007;13(3):332–9.PubMedCrossRef

20.

Illán-Gómez F, Gonzálvez-Ortega M, Orea-Soler I, et al. Obesity and inflammation: change in adiponectin, C-reactive protein, tumour necrosis factor-alpha and interleukin-6 after bariatric surgery. Obes Surg. 2012;22(6):950–5. doi:10.1007/s11695-012-0643-y.PubMedCrossRef

21.

Conroy R, Lee EJ, Jean A, et al. Effect of laparoscopic adjustable gastric banding on metabolic syndrome and its risk factors in morbidly obese adolescents. J Obes. 2011;2011:906384. doi:10.1155/2011/906384.PubMedCentralPubMedCrossRef

22.

Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292(14):1724–37.PubMedCrossRef

23.

Dixon JB, O’Brien PE, Playfair J, et al. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA. 2008;299(3):316–23. doi:10.1001/jama.299.3.316.PubMedCrossRef

24.

Holterman AX, Browne A, Dillard 3rd BE, et al. Short-term outcome in the first 10 morbidly obese adolescent patients in the FDA-approved trial for laparoscopic adjustable gastric banding. J Pediatr Gastroenterol Nutr. 2007;45(4):465–73.PubMedCrossRef

25.

Varady KA, Tussing L, Bhutani S, et al. Degree of weight loss required to improve adipokine concentrations and decrease fat cell size in severely obese women. Metabolism. 2009;58(8):1096–101. doi:10.1016/j.metabol.2009.04.010.PubMedCrossRef

26.

Cancello R, Henegar C, Viguerie N, et al. Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes. 2005;54(8):2277–86.PubMedCrossRef

Title: Laparoscopic Adjustable Gastric Banding Reduces Subcutaneous Adipose Tissue and Blood Inflammation in Nondiabetic Morbidly Obese Individuals
Authors: Laura Iaffaldano
Carmela Nardelli
Vincenzo Pilone
Giuseppe Labruna
Andreina Alfieri
Donatella Montanaro
Maddalena Ferrigno
Maria Restituta Zeccolella
Nicola Carlomagno
Andrea Renda
Alfonso Baldi
Pietro Forestieri
Lucia Sacchetti
Pasqualina Buono
Publication date: 01-12-2014
Publisher: Springer US
Published in: Obesity Surgery / Issue 12/2014
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI: https://doi.org/10.1007/s11695-014-1326-7

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Laparoscopic Adjustable Gastric Banding Reduces Subcutaneous Adipose Tissue and Blood Inflammation in Nondiabetic Morbidly Obese Individuals

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 12/2014

Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy for the Treatment of Morbid Obesity. A Prospective Study with 5 Years of Follow-Up

Internalized Weight Bias in Weight-Loss Surgery Patients: Psychosocial Correlates and Weight Loss Outcomes

Naming the Mini-Gastric Bypass

The True Incidence of Gastric GIST—a Study Based on Morbidly Obese Patients Undergoing Sleeve Gastrectomy

Obesity Surgery Journal—How Are We Doing?

The Impact of Obesity Surgery on Musculoskeletal Disease